Abstract. Ubiquitinated cytoplasmic inclusions (Ub-CIs) in superficial frontal cortex and dentate gyrus neurons are the hallmark of frontotemporal degeneration of the motor neuron disease-type (FTD-MND-type). To date, 2 reports have described intranuclear ubiquitinated inclusions (Ub-INIs) in 9 cases of familial FTD-MND-type (without clinical or pathologic motor neuron disease, MND). In the current study we found an additional 11 cases with Ub-INIs. We have identified for the first time among these cases 2 with a negative family history and 3 that have concomitant amyotrophic lateral sclerosis (ALS). The results of the present study i) confirm a previous report of significantly lower average brain weight and longer duration in cases with Ub-INIs, ii) reveal significantly greater striatal neuronal loss and gliosis in cases with intranuclear inclusions, and iii) demonstrate that intranuclear inclusions correlate with cytoplasmic inclusions and dystrophic neurites in frontal cortex and striatum but not in dentate gyrus. In addition, the current study confirms that Ub-INIs are found in familial FTD-MNDtype, but also extends the presence of Ub-INIs to familial FTD-MND (with concomitant ALS), and probably also to nonfamilial FTD-MND-type.
INTRODUCTION
Ubiquitinated cytoplasmic inclusions (Ub-CIs) have been described in the brains of amyotrophic lateral sclerosis (ALS) patients with or without dementia in neurons of the cortex and neostriatum (1) . Ub-CIs and dystrophic neurites (Ub-DNs) in the hippocampal dentate gyrus and superficial layers of frontal or temporal cortex or both are the defining pathologic features in the brains of those with frontotemporal degeneration of the motor neuron disease-type (FTD-MND-type) (2-6). FTD-MND-type was first described in the brains of demented ALS patients (4, 5) , but was subsequently also found as the pathologic substrate of a subset of frontotemporal dementias (FTDs) in the absence of ALS (2, 3, 6) . In fact, FTD-MND-type is likely the most common of the FTD subtypes (7) . The terminology of this type of FTD can be confusing. It has been called frontotemporal degeneration with ubiquitinated inclusions, FTD with ubiquitin-positive, tau and alpha-synuclein-negative inclusions, and in the United Kingdom it is called motor neuron disease inclusion dementia. However, at a recent consensus conference the following terminology was agreed upon: FTD of the motor neuron disease-type (FTD-MND-type) when ALS is absent, and FTD with motor neuron disease (FTD-MND) when clinical and pathologic ALS is present (2, 3) .
FTD-MND-type remains virtually the only neurodegenerative disorder characterized by insoluble inclusions and deposits labeled by ubiquitin only. Lewy bodies, also labeled with ubiquitin, were shown several years ago to be comprised predominantly of ␣-synuclein. A subset of the neurofibrillary tangles and dystrophic neurites in senile plaques of Alzheimer disease (AD) are also labeled by ubiquitin, as are a subset of the insoluble deposits in the familial and sporadic tauopathies, although the major protein component of the deposits in AD as well as the tauopathies is, of course, tau. While it is almost certain that the major protein component of the inclusions in FTD-MND-type is not ubiquitin alone, and that the identity of this protein will at some point in the future be determined, currently these inclusions are labeled by ubiquitin only.
Two recent studies (8, 9) have described an intranuclear location of similar ubiquitinated inclusions (UbINIs) in a total of 9 cases of FTD-MND-type. Ub-INIs were found in neurons of superficial frontal cortex and dentate gyrus neurons, but were most numerous in the striatum. In none of these 9 cases was there concomitant clinical or pathologic MND and all 9 cases were familial.
BIGIO ET AL

J Neuropathol Exp Neurol, Vol 63, August, 2004
We evaluated 34 cases of pathologically defined FTD-MND in our files (22 with concomitant clinical and pathologic ALS, defined as FTD-MND, and 12 without ALS, defined as FTD-MND-type) for the presence of Ub-INIs. We compared these cases to 11 cases of ALS without FTD-MND (5 were sporadic and 6 familial).
MATERIALS AND METHODS
Cases
The 34 cases chosen for the study had, by definition, UbCIs, Ub-DNs, or both, in dentate gyrus or superficial frontal cortex or both (Tables 1, 2 ). Twenty-three of these had clinical dementia. Twelve had pathologic FTD-MND-type alone (2, 3), without clinical or pathologic ALS (8 males and 4 females; a male:female ratio of 2:1). Twenty-two had concomitant clinical and pathologic ALS (15 males and 7 females; a male:female ratio of approximately 2:1), ''FTD-MND'' in the accepted nomenclature (2, 3) . Of these 22 cases, 9 subjects (6 males, 3 females) had the clinical diagnosis of ALS but did not clinically have dementia, and thus were given the pathologic diagnosis of ''FTD-MND pathology,'' indicating that they had the pathology of FTD-MND, but not clinical dementia. We compared these 34 cases to 11 cases with clinical and pathologic ALS only (7 males and 4 females), 5 sporadic (3 males, 2 females), and 6 familial (4 males, 2 females).
Family histories of the subjects of this study are detailed in Table 2 . In Table 3 , subjects with a family history of clinically diagnosed or autopsy-proven FTD or ALS or both in at least 1 family member are designated ''ϩϩ'' in column 2 of Table 3 . Subjects with a family history of neurodegenerative (such as AD, primary progressive aphasia, corticobasal ganglionic degeneration, or simply dementia) or psychiatric disease not FTD or ALS in at least 1 family member are designated ''ϩ'' in column 2 of Table 3 . We included psychiatric disease and alternative types of dementia in a family member in this category because subjects with FTD are occasionally misdiagnosed with disorders such as schizophrenia, bipolar disorder, and other dementias such as AD. When the family history was unknown we indicated this in column 2 of Table 3 , and when there was no family history of any neurodegenerative or psychiatric disorder there is a ''0'' in this column. According to these criteria, 26 cases (cases 1-9, 12-22, and 40-45) were familial. Eight of the familial cases had FTD-MND-type, 12 had either FTD-MND or the pathology of FTD-MND without a clinical history of dementia (FTD-MND pathology), and 6 had ALS.
Pathologic Evaluation (Table 3) In most cases, all cortical lobes, subcortical gray matter regions, cerebellum, brainstem at all 3 levels, and spinal cord at cervical, thoracic, and lumbosacral levels were sampled and examined with routine hematoxylin and eosin (H&E) stain. None of the cases had brainstem Lewy bodies. Sections of dentate gyrus, frontal lobe, and striatum were stained immunohistochemically using antibodies to tau (AT8, monoclonal, 1:200, Pierce Biotechnology, Rockford, IL) and ubiquitin (polyclonal, 1:200, Dako, Carpinteria, CA) and examined for inclusions and deposits. Ub-CIs, Ub-DNs, and Ub-INIs were semiquantitated (absent, sparse, moderate, or frequent) in all regions.
The diagnosis of FTD-MND was based on consensus criteria (2, 3) . Briefly, criteria include the presence of circumscribed frontal and temporal atrophy, variable caudate atrophy, and nigral pallor with associated variable neuronal loss and gliosis in both regions, cortical layer II microvacuolation in frontal or temporal lobes or both, and ubiquitin-positive, tau and alphasynuclein-negative, cytoplasmic inclusions and dystrophic neurites in superficial frontal cortex or dentate gyrus neurons or both. Ubiquitinated inclusions were determined to be intranuclear (Ub-INI) when the nuclear shape was distorted by the elongated structure of the inclusions, which often had tapering ends (cigar-shaped), or when an inclusion was clearly within the confines of the nucleus and in the same plane of section, which included round intranuclear inclusions most likely cut transversely. Intranuclear inclusions were frequently separated from the surrounding ''nucleoplasm'' by a clear halo.
Statistical Analysis
Age at onset, age at death, duration and brain weight were compared between groups of cases using the Wilcoxon rank sum test. Family history, gender, and pathologic characteristics were compared between groups of cases using the Fisher exact test. A p value less than 0.05 was considered significant.
RESULTS (Tables 1, 3)
Males predominated in the FTD cases (M:F ratio 23: 11, ϳ2:1), both with ALS (M:F ratio 15:7 ϳ2:1) and without (M:F ratio 8:4 ϭ 2:1). The average age of onset in FTD-MND-type was 59.8 years, while in FTD-MND it was 57.6 years (p ϭ 0.58), and the average age at death in FTD-MND-type was 65.2 years compared to 60.9 for FTD-MND (p ϭ 0.19). The average duration for FTD-MND-type was 6.0 years, significantly longer than the 2.9 years duration for FTD-MND (p ϭ 0.002). The average age of onset in all familial FTDs (58.1) was only a year younger than in sporadic FTDs (59.0) (p ϭ 0.91). Not surprisingly, the average age of onset for familial ALS (54.4 years) was younger than in sporadic ALS (60.0 years), although this difference did not reach statistical significance (p ϭ 0.21). Disease duration was significantly shorter in subjects with ALS with and without FTD (ALS ϩ FTD-MND ϩ FTD-MND pathology, 2.8 years) compared to the group of FTD subjects without ALS (FTD-MND-type, 6.0 years) (p ϭ 0.0003), but there was no significant difference in duration between ALS subjects with FTD (FTD-MND ϩ FTD-MND pathology 2.9 years) or without FTD (ALS alone, 2.3 years, p ϭ 0.25).
The focus of our study was to determine the prevalence of Ub-INIs in FTD-MND and FTD-MND-type, to evaluate for the presence of Ub-INIs in ALS, and to compare clinical and pathologic differences between cases with and without Ub-INIs. Eleven cases (cases 1-11) had such inclusions (Table 3) , most numerous in the striatum in cases 1-3, 6, 8, and 9 ( Fig. 1 ) and in the frontal lobe in cases 4 and 11. The frequencies of Ub-INIs in frontal , and 10 had a negative family history (cases 25-34). There was no significant difference in family history between cases with and without Ub-INIs (p ϭ 0.14), and separating a positive family history into those with a family history of FTD or ALS and those with a family history of non-FTD or ALS neurodegenerative or psychiatric disorder made no additional difference (p ϭ 0.22). In addition, although the ratio of males to females in cases with UbINIs (4.5:1) was 3 times that of cases without Ub-INIs (1.5:1), the difference was not statistically significant (p ϭ 0.27). There was no significant difference between average age onset (p ϭ 0.13) and average age at death (p ϭ 0.65), although duration of disease in cases with UbINIs (5.5 years) was significantly longer than those without (3.3 years, p ϭ 0.047).
The average brain weight of FTDs with intranuclear inclusions (1118 grams) was significantly lower than that of FTDs without Ub-INIs (1238 grams, p ϭ 0.044). Moderate to severe atrophy of both frontal lobe and striatum was more common in cases with intranuclear inclusions, but this difference was not statistically significant (frontal atrophy p ϭ 0.30, striatal atrophy p ϭ 0.21). However, neuronal loss and gliosis in the striatum was significantly greater in cases with intranuclear inclusions (p ϭ 0.002).
Frontal Ub-INIs were sparse in 6 cases (cases 1, 3, and 5-8), moderate in cases 2 (Fig. 2, left) and 10, and frequent in cases 4 (Fig. 2, right) and 11. All 11 cases with Ub-INIs also had frontal Ub-CIs and 9 had frontal UbDNs (Fig. 3, case 2 ), 9 had striatal Ub-CIs, (Fig. 4 , case 9), and 8 had dentate gyrus neuronal Ub-CIs (Fig. 5, The ALS pathology in cases with Ub-INIs (cases 4, 5, and 9), as in cases of ALS without Ub-INIs, included mild Betz cell loss in the motor cortex, mild to severe neuronal loss and gliosis in the hypoglossal nucleus (Fig.  6a, case 4) , mild to severe degeneration of ventral and lateral corticospinal tracts, and moderate to severe neuronal loss and gliosis in spinal cord anterior horns. There were sparse to moderate Bunina bodies (Fig. 6b, case 4) , sparse to moderate ubiquitin-positive skein-like inclusions (Fig. 6c, case 9 ) and sparse Lewy-like bodies (Fig.  6d, case 9 ) in anterior horn neurons. There was significant degeneration in spinal anterior compared to posterior nerve roots (Fig. 6e, case 9) . None of the ALS cases without FTD, either sporadic or familial, contained ubiquitinated cytoplasmic inclusions, dystrophic neurites, or intranuclear inclusions.
DNA was analyzed for SOD-1 mutations in cases 2-5, 9-11, 14-20, 26-30, 35-37, and 39-45. SOD-1 mutations were identified in 2 familial ALS cases only (without FTD-MND): one exon 1 A4V mutation (case 42) and one exon 4 G85R mutation (case 41). ApoE genotyping was performed in most of the cases. Twentyfour of 32 cases had the ApoE 3,3 genotype, 5 cases were ApoE 3,4, and 3 cases were ApoE 2,3 (Table 3 ). There was no significant difference in ApoE genotype between cases with and without Ub-INIs (p ϭ 0.99). Mutation analysis of tau exons 9-13 was performed on cases 4, 9, 19, 22, 24, 28-30, 40, and 43 and no tau mutations were identified.
DISCUSSION
As in 2 previous reports (8, 9) , the current study found Ub-INIs in familial FTD-MND-type cases (cases 1-9), and there were also familial cases (cases 12 and 13) without Ub-INIs. In addition, for the first time, 2 cases with Ub-INIs appear to be non-familial (cases 10 and 11). Abbreviations: ALS ϭ amyotrophic lateral sclerosis; atr ϭ atrophy; CBGD ϭ corticobasal ganglionic degeneration; CI ϭ cytoplasmic inclusions; dem ϭ dementia; Dent ϭ dentate gyrus; DN ϭ dystrophic neurites; FALS ϭ familial ALS; FH ϭ family history; FL ϭ frontal lobe; FLD ϭ frontal lobe dementia; FTD ϭ frontotemporal degeneration; FTD-MND ϭ FTD with motor neuron disease; FTD-MND-type ϭ FTD of the motor neuron disease type; FTD-MND path. ϭ has the pathology of FTD-MND but did not have clinical dementia; INI ϭ intranuclear inclusions; MND ϭ motor neuron disease; N/A ϭ not available; nlg ϭ neuronal loss and gliosis; path. ϭ pathology; Pathologic dx ϭ pathologic diagnosis; PPA ϭ primary progressive aphasia; PRAD ϭ probable Alzheimer disease; SALS ϭ sporadic ALS; Str ϭ striatal; Ub ϭ ubiquitin; unk ϭ unknown. 0 ϭ absent or negative; ϩ ϭ sparse; ϩϩ ϭ moderate; ϩϩϩ ϭ frequent (except in FH column, see legend below). * ϭ genetic testing not performed. Organization of table: FTD cases are first grouped on the basis of presence (cases 1-11) or absence (cases 12-34) of intranuclear inclusions. Next, within these major groups, the first cases listed are those with family history or autopsy proven diagnosis in at least 1 family member of FTD or ALS (ϩϩ in FH column), next are those with a family history of neurodegenerative or psychiatric disease not FTD or ALS (ϩ in FH column), then those whose family histories are unknown (FH unk.), and lastly, those with a negative family history (FH 0). Then, within these family history groups, cases are listed in order of pathologic diagnoses beginning with FTD-MND-type, next FTD-MND, and lastly FTD-MND path (those with pathologic FTD-MND who were never diagnosed during life with cognitive dysfunction). The ALS cases (35-45) are last, with familial listed before sporadic. However, we interpret a negative family history with caution. First, there may be missing or incorrect information in self-reported family histories, and second, issues of paternity could be raised. Thirdly, and possibly more importantly, in case 10 the patient's mother died at age 56 of hepatic carcinoma, an age 6 years younger than that of the patient when he first developed cognitive problems. It is possible that had she lived longer, she might have developed a similar disorder. We were unable to learn whether additional members of her family had neurologic or cognitive disorders.
In addition, and also for the first time, Ub-INIs were found in 3 cases of familial FTD-MND (i.e. having concomitant clinical and pathologic ALS; cases 4, 5, and 9). This is a clear association, because all 3 cases had clinical histories of muscle weakness combined with pathologic findings of ALS. Because Ub-INIs had previously been identified in only 9 cases, and because there appears to be an intimate relationship between ALS and FTD-MNDtype, it is not surprising that Ub-INIs have eventually been found in FTD-MND (i.e. with concomitant ALS). , ϫ600) . Fig. 3 . Ub-CIs and DNs, frontal lobe, case 2 (ubiquitin, ϫ400). Fig. 4 . Ub-CIs, caudate, case 9, familial FTD-MND (ubiquitin, ϫ600). Fig. 5 . Ub-CIs, dentate gyrus, case 9 (ubiquitin, ϫ400).
Woulfe et al reported that cases with Ub-INIs had a younger age onset, prolonged duration, absence of motor symptoms, and positive family history (8) . In the current study, cases with Ub-INIs had an average 3.8 years younger onset than those without, but this difference was not statistically significant. Average duration in the cases with Ub-INIs was nearly twice as long as those without, and this difference was statistically significant. Eight of the 11 cases with Ub-INIs had no motor symptoms while 3 had both motor symptoms and the associated pathology of ALS. Additionally, 4 of the FTD cases without UbINIs did not have motor symptoms and 19 had both the symptoms and pathology of ALS. Therefore, the absence of motor symptoms in the current study also correlated with the presence of Ub-INIs. Nine of 11 cases (82%) with Ub-INIs were familial, and 11 of the 21 cases (52%) without Ub-INIs for whom family history information was known were also familial, and so while the association of family history with Ub-INIs was not statistically significant, family history was more likely to be positive when Ub-INIs were present than when they were not.
Woulfe et al also observed that cases with Ub-INIs more commonly had striatal atrophy and that this group had a lower average brain weight (8) . In the current study, 4 of the 10 cases with Ub-INIs (for which we had gross information) had moderate to severe striatal atrophy, while only 1 of the 14 cases without Ub-INIs (for which we had gross information) had moderate to severe striatal atrophy, but this difference was not statistically significant. However, greater neuronal loss and gliosis in the striatum in cases with Ub-INIs compared to those without was statistically significant. The average brain weight of the group of FTD cases with Ub-INIs (1,118 grams) was lower than that of the group of FTD cases without Ub-INIs (1,238 grams) and this difference was also statistically significant.
Houropian et al described the combination of motor neuron disease with clinical and pathologic FTD in 1984 (10) . Ub-CIs have been described in the dentate gyrus and superficial frontal cortex in cases of demented patients both with (4, 5) and without ALS (6) , and in the neostriatum of sporadic and familial ALS patients with and without dementia (1). In 1996, Ub-CIs in the dentate granule cells were reported in a case of familial ALS with a mutation in exon 4 of the SOD-1 gene (11). More recently, it was reported that some cases of FTD-ALS show linkage to chromosome 9 (12). This paper, however, lacks a description of the pathology of these chromosome 9-linked cases and, specifically, whether there were ubiquitinated inclusions (12) . Ubiquitin-positive, tau and alpha-synuclein-negative inclusions are therefore linked to both FTD and ALS in what appears to be a spectrum of disorders from FTD to FTD-MND to ALS, without specificity for either ALS or FTD.
The chromosomal mutation associated with these familial FTDs is unknown. There have not yet been sufficient numbers of affected family members to do linkage analysis on the cases with Ub-INIs. It would be interesting to know if there is linkage to chromosome 9, and conversely, whether the families with FTD-ALS linked to chromosome 9 have Ub-INIs (12) . No SOD-1 mutations were found in the 19 FTD cases in the current study for which this analysis could be performed.
Examining this problem from another direction, the major protein component of the ubiquitinated cytoplasmic and intranuclear inclusions and dystrophic neurites in FTD-MND and FTD-MND-type remains unknown. These inclusions have not been labeled by any immunostains, including cystatin-C, which labels Bunina bodies in ALS, and neurofilament, which labels spheroids and basophilic inclusions in ALS. The nature of Ub-CIs, Ub-DNs, and Ub-INIs, including their very small size and sparse distribution, makes their isolation and subsequent identification difficult. For success with laser capture techniques, capture of perhaps thousands of inclusion-containing cells is required. It is not clear at present whether the cytoplasmic and intranuclear inclusions are comprised of the same protein. If so, the presence in some cases of the inclusions in both cytoplasmic and intranuclear cellular compartments may be a clue to the identity of this protein.
The strong correlation of striatal or frontal Ub-INIs with moderate or frequent CIs and the somewhat weaker correlation with moderate or frequent DNs, and the lack of correlation with moderate or frequent CIs or DNs in the dentate gyrus were particularly interesting. Ub-INIs in the dentate gyrus are relatively uncommon and were observed in only 2 cases in the present study (cases 4 and 9). This observation raises the possibility that intranuclear inclusions begin to appear when the frequencies of ubiquitinated cytoplasmic aggregates and dystrophic neurites reach a particular threshold. Is some cellular . ALS pathology, cases 4 and 9. a: Hypoglossal nucleus neuronal loss and gliosis, case 4 (H&E, ϫ200). b: Cervical cord anterior horn neuron, Bunina body, case 4 (H&E, ϫ600). c: Lumbosacral cord anterior horn neuron, skein-like inclusion, case 9 (ubiquitin, ϫ600). d: Lumbosacral cord anterior horn neurons, one with Lewy like body (upper right corner) and one with skein-like inclusion (lower left corner), case 9 (ubiquitin, ϫ600). e: Cervical anterior (left) atrophic nerve roots compared to posterior (right) nerve roots without atrophy, case 9 (both H&E, ϫ200). mechanism overwhelmed at this threshold, resulting in translocation of the aggregated protein from the cytoplasm into the nucleus? If so, are the cytoplasmic and possibly the intranuclear aggregates protective or are they pathogenic? Perhaps rather than the hypothesis that some threshold is reached, resulting in translocation of aggregates from the cytoplasm to the nucleus, the undefined genetic mutation(s) present in familial cases allows aggregates to accumulate in both compartments. These issues are similar to those raised in attempting to understand the pathogenesis of the trinucleotide repeat disorders. In fact, the parallels between trinucleotide repeat disorders and FTD-MND or FTD-MND-type with intranuclear inclusions are intriguing. Trinucleotide repeat disorders are virtually always familial, and 18 of 20 cases with Ub-INIs in the literature (refs. 8, 9 , and the current study) are familial. In both, there is gross atrophy and neuronal loss and gliosis in the frontal lobe and striatum, and there are cytoplasmic and intranuclear aggregates of ubiquitinated protein in these locations. Woulfe et al found no trinucleotide expansion mutations in genes encoding huntingtin, atrophin, androgen receptor, and ataxins 1-3, 6, and 7 in the analysis performed on 1 of 3 cases studied (8) . Identification of the gene(s) and protein(s) involved in FTD-MND and FTD-MND-type would undoubtedly contribute to the understanding of these disorders.
Like Woulfe et al (8) , in the current study, cases with Un-INI had significantly longer disease duration, absence of motor symptoms, and lower average brain weights. Findings that were confirmed but were not statistically significant included younger average age of onset, positive family history, and striatal atrophy. New and significant findings from the current study in cases with UbINIs are greater neuronal loss and gliosis in the striatum and greater frequencies of moderate or frequent frontal and striatal CIs and DNs but no correlation between UbINIs and moderate or frequent dentate gyrus CIs or DNs. In addition, for the first time, 2 cases with Ub-INIs had an apparently negative family history, and 3 cases had concomitant clinical and pathologic ALS. Given the apparent clinicopathologic spectrum of the FTD to FTD-MND to ALS disorders, we would predict that Ub-INIs
